Retatrutide – Triple Incretin Analog for Research

Retatrutide is an investigational peptide designed as a triple receptor agonist for GLP-1, GIP, and glucagon pathways. This multi-receptor activation provides a broad mechanism of action studied in metabolic, endocrine, and appetite regulation research.

Each vial contains 20mg of high-purity Retatrutide, produced under stringent conditions for in vitro research studies.

Research Applications

• GLP-1, GIP, and glucagon receptor co-agonist studies
• Glucose metabolism and insulin sensitivity research
• Appetite suppression and satiety modeling
• Metabolic balance and weight regulation
• Energy expenditure and endocrine function studies

Scientific Background

Retatrutide differs from earlier incretin analogs by engaging three metabolic receptors simultaneously. Research suggests that activating GLP-1, GIP, and glucagon pathways may provide additive effects on glucose control, energy expenditure, and appetite regulation. Its unique multi-targeted profile positions it alongside dual incretin compounds like Tirzepatide while expanding the potential scope of incretin-based research.

Chemical Profile

Type: Triple incretin receptor agonist
Targets: GLP-1, GIP & glucagon receptors
Form: Lyophilized powder
Purity: ≥98% (HPLC)

Produced under GMP-grade standards for laboratory research only.

Storage & Handling

Store at −20°C in a cool, dry environment. After reconstitution, refrigerate at 2–8°C and use within stability guidelines. Avoid repeated freeze–thaw cycles.

For Research Use Only

Retatrutide 20mg is intended strictly for in vitro laboratory research and is not for human or veterinary use.

• Retatrutide – Wikipedia
• GLP-1 – Wikipedia
• GIP – Wikipedia
• Glucagon – Wikipedia